PHILADELPHIA (WPVI) -- The FDA is investigating an alarming finding on a promising cancer therapy invented at Penn Medicine. It's being linked to rare, secondary cancers. The agency said it received ...

It may be scary, but the truth is cancers occur in our bodies all the time. One study — on the tonsils of young people — found two-thirds contained abnormalities that could lead to cancer. Obviously, ...

Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the odds for a secondary cancer later, a new study shows. Researchers at Memorial ...

Cancer has long been a formidable foe, but recent breakthroughs in immunotherapy have brought new hope to patients. Among these advances, chimeric antigen receptor T-cell therapy (CAR-T) stands out as ...

EU regulators are requiring makers of CART T cell therapies to update their product labeling to include information that recipients may be at increased risk for developing secondary T cell cancers.